


Claims


1. Use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of HIV infection wherein the compound of formula (I) is a compound of formula



5

a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

A and B each represents a radical of formula



wherein

10 ring E represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;
ring F represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;
R¹ represents hydrogen; aryl; formyl; C₁-6alkylcarbonyl; C₁-6alkyloxycarbonyl;
C₁-6alkyl optionally substituted with formyl, C₁-6alkylcarbonyl,
C₁-6alkyloxycarbonyl, C₁-6alkylcarbonyloxy; or C₁-6alkyloxyC₁-6alkylcarbonyl
15 substituted with C₁-6alkyloxycarbonyl;

R² represents cyano; aminocarbonyl; mono- or di(C₁-4alkyl)aminocarbonyl; C₁-6alkyl
optionally substituted with cyano, aminocarbonyl or mono- or
di(C₁-4alkyl)aminocarbonyl; C₂-6alkenyl substituted with cyano, aminocarbonyl or
mono- or di(C₁-4alkyl)aminocarbonyl; or C₂-6alkynyl substituted with cyano,
aminocarbonyl or mono- or di(C₁-4alkyl)aminocarbonyl;

20 X₁ represents -NR⁵-; -NH-NH-; -N=N-; -O-; -C(=O)-; -C₁-4alkanediyl-; -CHOH-; -S-;
-S(=O)_p-; -X₂-C₁-4alkanediyl-; -C₁-4alkanediyl-X₂-; or
-C₁-4alkanediyl-X₂-C₁-4alkanediyl-;

X₂ represents -NR⁵-; -NH-NH-; -N=N-; -O-; -C(=O)-; -CHOH-; -S-; or -S(=O)_p-;

25 m represents an integer of value 1, 2, 3 or 4;

R³ represents cyano; aminocarbonyl; amino; halo; NHR¹³; NR¹³R¹⁴; -C(=O)-NHR¹³;
-C(=O)-NR¹³R¹⁴; -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶; C₁-6alkyl optionally
substituted with one or more substituents each independently selected from R^{3a};
C₁-6alkyloxy optionally substituted with one or more substituents each independently
30 selected from R^{3a}; C₁-6alkyloxyC₁-6alkyl optionally substituted with one or more
substituents each independently selected from R^{3a}; C₂-6alkenyl optionally substituted
with one or more substituents each independently selected from R^{3a}; C₂-6alkynyl

optionally substituted with one or more substituents each independently selected from R^{3a}; -C(=N-O-R⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷;
R^{3a} represents halo, cyano, hydroxy, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl,
-C(=O)-O-C₁₋₆alkyl, -C(=O)-polyhaloC₁₋₆alkyl, -C(=O)-O-polyhaloC₁₋₆alkyl or R⁷;

5 X₃ represents -NR⁵-; -NH-NH-; -N=N-; -O-; -C(=O)-; -S-; -S(=O)_p-;
-X_{4a}-C₁₋₄alkanediyl-; -C₁₋₄alkanediyl-X_{4b}-; -C₁₋₄alkanediyl-X_{4a}-C₁₋₄alkanediyl-;
or -C(=N-OR⁸)-C₁₋₄alkanediyl-;
X_{4a} represents -NR⁵-; -NH-NH-; -N=N-; -C(=O)-; -S-; or -S(=O)_p-;
X_{4b} represents -NH-NH-; -N=N-; -O-; -C(=O)-; -S-; or -S(=O)_p-;
10 each R⁴ independently represents hydroxy; halo; C₁₋₆alkyl optionally substituted with
one or more substituents each independently selected from R^{4a}; C₂₋₆alkenyl optionally
substituted with one or more substituents each independently selected from R^{4a};
C₂₋₆alkynyl optionally substituted with one or more substituents each independently
selected from R^{4a}; C₃₋₇cycloalkyl; C₁₋₆alkyloxy; C₁₋₆alkyloxycarbonyl;
15 C₁₋₆alkylcarbonyloxy; carboxyl; formyl; cyano; nitro; amino; mono- or
di(C₁₋₆alkyl)amino; polyhaloC₁₋₆alkyl; polyhaloC₁₋₆alkyloxy; polyhaloC₁₋₆alkylthio;
-S(=O)_pR⁶; -NH-S(=O)_pR⁶; -C(=O)R⁶; -NHC(=O)H; -C(=O)NH₂; NHC(=O)R⁶;
C(=NH)R⁶; or R⁷;
R^{4a} represents halo, cyano, NR⁹R¹⁰, hydroxy or -C(=O)R⁶;

20 R⁵ represents hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl;
C₁₋₆alkyl optionally substituted with formyl, C₁₋₆alkylcarbonyl,
C₁₋₆alkyloxycarbonyl or C₁₋₆alkylcarbonyloxy; or C₁₋₆alkyloxyC₁₋₆alkylcarbonyl
substituted with C₁₋₆alkyloxycarbonyl;
R⁶ represents C₁₋₆alkyl, amino, mono- or di(C₁₋₄alkyl)amino or polyhaloC₁₋₄alkyl;

25 R⁷ represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic,
bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic
aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a
monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic,
bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or
30 heterocyclic ring systems may, whenever possible, optionally be substituted with
one, two, three, four or five substituents each independently selected from halo,
hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or
di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl,
C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro,
35 polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O-R⁸), R^{7a},
-X₃-R^{7a} or R^{7a}-C₁₋₄alkanediyl-;

R^{7a} represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic, bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁-6alkyl, hydroxyC₁-6alkyl, aminoC₁-6alkyl, mono or di(C₁-6alkyl)aminoC₁-6alkyl, formyl, C₁-6alkylcarbonyl, C₃₋₇cycloalkyl, C₁-6alkyloxy, C₁-6alkyloxycarbonyl, C₁-6alkylthio, cyano, nitro, polyhaloC₁-6alkyl, polyhaloC₁-6alkyloxy, aminocarbonyl, -CH(=N-O-R⁸);

R⁸ represents hydrogen, C₁₋₄alkyl optionally substituted with aryl, or aryl;

R⁹ and R¹⁰ each independently represent hydrogen; hydroxy; C₁-6alkyl; C₁-6alkyloxy; C₁-6alkylcarbonyl; C₁-6alkyloxycarbonyl; amino; mono- or di(C₁-6alkyl)amino; mono- or di(C₁-6alkyl)aminocarbonyl; -CH(=NR¹¹) or R⁷, wherein each of the aforementioned C₁-6alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁-6alkyloxy, hydroxyC₁-6alkyloxy, carboxyl, C₁-6alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁-4alkyl)amino, polyhaloC₁-4alkyl, polyhaloC₁-4alkyloxy, polyhaloC₁-4alkylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, or R⁷; or

R⁹ and R¹⁰ may be taken together to form a bivalent or trivalent radical of formula

-CH₂-CH₂-CH₂-CH₂- (d-1);

-CH₂-CH₂-CH₂-CH₂-CH₂- (d-2);

-CH₂-CH₂-O-CH₂-CH₂- (d-3);

-CH₂-CH₂-S-CH₂-CH₂- (d-4);

-CH₂-CH₂-NR¹²-CH₂-CH₂- (d-5);

-CH₂-CH=CH-CH₂- (d-6); or

=CH-CH=CH-CH=CH- (d-7);

R¹¹ represents cyano; C₁-4alkyl optionally substituted with C₁-4alkyloxy, cyano, amino, mono- or di(C₁-4alkyl)amino or aminocarbonyl; C₁-4alkylcarbonyl; C₁-4alkyloxycarbonyl; aminocarbonyl; mono- or di(C₁-4alkyl)aminocarbonyl;

R¹² represents hydrogen or C₁-4alkyl;

R¹³ and R¹⁴ each independently represent C₁-6alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁-4alkyl)aminocarbonyl; C₂-6alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁-4alkyl)aminocarbonyl;

C₂-alkynyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹⁵ represents C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

5 R¹⁶ represents C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or R⁷;

-C-D- represents a bivalent radical of formula

-N=CH-NR¹⁷- (c-1); or

-NR¹⁷-CH=N- (c-2);


10 R¹⁷ represents hydrogen; C₁₋₆alkyl optionally substituted with hydroxy, cyano, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₁₋₄alkyloxycarbonyl or aryl; p represents an integer of value 1 or 2;

aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, R⁷ or -X₃-R⁷;

15 provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a).

20 2. A compound as defined in claim 1 provided that when R² represents aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl then R³ represents cyano; -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶; C₁₋₆alkyl substituted with one or more substituents each independently selected from R^{3b}; C₁₋₆alkyloxy substituted with one or more substituents each independently selected from R^{3a}; C₁₋₆alkyloxyC₁₋₆alkyl optionally substituted with one or more substituents each independently selected from R^{3a}; C₂₋₆alkenyl optionally substituted with one or more substituents each independently selected from R^{3a}; C₂₋₆alkynyl optionally substituted with one or more substituents each independently selected from R^{3a}; -C(=N-O-R⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷; with R^{3b} representing cyano, hydroxy, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl, -C(=O)-polyhaloC₁₋₆alkyl, -C(=O)-O-polyhaloC₁₋₆alkyl or R⁷.


30 3. A compound according to claim 2 wherein the compound has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,
wherein R¹, R², R³, R⁴, ring E, ring F, C, D and m are as defined in claim 1.


5

4. A compound according to claim 3 wherein the compound of formula (I-A) has the formula




a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,
wherein R¹, R², R³, R⁴, ring E, ring F, C and D are as defined in claim 1.

10 5. A compound according to claim 2 wherein the compound has the formula



15 a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,
wherein R¹, R², R³, R⁴, ring E, ring F, C, D and m are as defined in claim 1.


20 6. A compound according to claim 5 wherein the compound of formula (I-B) has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof,
wherein R^1 , R^2 , R^3 , R^4 , ring E, ring F, C and D are as defined in claim 1.

5

7. A compound according to any one of claims 2 to 6 wherein ring E is phenyl.
8. A compound according to any one of claims 2 to 7 wherein ring F is phenyl.
- 10 9. A compound according to claim 2 wherein the compound has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

$-a^1 = a^2 - C(R^2) = a^3 - a^4$ represents a bivalent radical of formula

15 -CH=CH-C(R²)=CH-CH= (a-1);

$$-\text{N}=\text{CH}-\text{C}(\text{R}^2)=\text{CH}-\text{CH}=\quad \quad \quad (\text{a-2})$$

$$-\text{CH}=\text{N}-\text{C}(\text{R}^2)=\text{CH}-\text{CH} \equiv \quad (\text{a-3})$$

$$-\text{N}=\text{CH}-\text{C}(\text{R}^2)=\text{N}-\text{CH}-$$

$$\text{N}-\text{CH}_2\text{C}(\text{R}^2)-\text{CH}_2\text{N}- \quad (\text{e}, \text{s})$$

$$\text{CH}_2\text{N}(\text{C}(\text{R}^2)^2)\text{N}(\text{CH}_2)$$

$$-CH=N-C(R')=N-CH= \quad (a-b), \text{ or} \\ -N=N-C(R')^2-CH_2-CH_2 \quad (c-d)$$

$$-\text{N}=\text{N}-\text{C}(\text{R}^{\text{-}})=\text{CH}-\text{CH}=\quad \quad \quad (\text{a-7});$$

$\text{--b}^{\cdot} = \text{b}^{\cdot} -$ represents a bivalent radical

$$-\text{CH}=\text{CH}-\text{CH}=\text{CH}- \quad (b-1)$$

-N=CH-N=CH- (b-3);
-N=CH-CH=N- (b-4); or
-N=N-CH=CH- (b-5);

-C-D- represents a bivalent radical of formula

5 -N=CH-NR¹⁷- (c-1); or
-NR¹⁷-CH=N- (c-2);

m represents an integer of value 1, 2, 3 and in case $-b^1=b^2-b^3=b^4$ is (b-1), then m may also be 4;

R¹ represents hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl;

10 C₁₋₆alkyl optionally substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy; or C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxycarbonyl;

R² represents cyano; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl; C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or

15 di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or C₂₋₆alkynyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

X₁ represents -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, C₁₋₄alkanediyl, -CHOH-, -S-, -S(=O)_p-, -X₂-C₁₋₄alkanediyl- or -C₁₋₄alkanediyl-X₂-,

20 X₂ represents -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)_p-,

R³ represents NHR¹³; NR¹³R¹⁴; -C(=O)-NHR¹³; -C(=O)-NR¹³R¹⁴; -C(=O)-R¹⁵; -CH=N-

NH-C(=O)-R¹⁶; cyano; halo; C₁₋₆alkyl; polyhaloC₁₋₆alkyl; C₁₋₆alkyl

substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyl substituted

25 with hydroxy and a second substituent selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxyc₁₋₆alkyl optionally substituted with

one or more substituents each independently selected from cyano, NR⁹R¹⁰,

-C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxy optionally substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰,

30 -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkenyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰,

-C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkynyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰,

-C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; -C(=N-O-R⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷;

35 X₃ is -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)_p-, -X_{4b}-C₁₋₄alkanediyl-,

-C₁₋₄alkanediyl-X_{4a}-, -C₁₋₄alkanediyl-X_{4b}-C₁₋₄alkanediyl,

-C(=N-OR⁸)-C₁₋₄alkanediyl-;

with X_{4a} being $-\text{NH}-\text{NH}-$, $-\text{N}=\text{N}-$, $-\text{O}-$, $-\text{C}(=\text{O})-$, $-\text{S}-$, $-\text{S}(=\text{O})_p-$; and
with X_{4b} being $-\text{NH}-\text{NH}-$, $-\text{N}=\text{N}-$, $-\text{C}(=\text{O})-$, $-\text{S}-$, $-\text{S}(=\text{O})_p-$;
each R^4 independently represents halo, hydroxy, C_{1-6} alkyl, C_{3-7} cycloalkyl,
 C_{1-6} alkyloxy, hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, cyano, nitro, polyhalo C_{1-6} alkyl,
5 polyhalo C_{1-6} alkyloxy, aminocarbonyl, mono- or di(C_{1-4} alkyl)aminocarbonyl,
 C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyl, formyl, amino, mono- or
di(C_{1-4} alkyl)amino or R^7 ;
 R^5 is hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl
optionally substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl or
10 C_{1-6} alkylcarbonyloxy; or C_{1-6} alkyloxy C_{1-6} alkylcarbonyl substituted with
 C_{1-6} alkyloxycarbonyl;
 R^6 is C_{1-4} alkyl, amino, mono- or di(C_{1-4} alkyl)amino or polyhalo C_{1-4} alkyl;
 R^7 is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic
carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or
15 aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems
may optionally be substituted where possible with one, two, three, four or five
substituents each independently selected from halo, hydroxy, mercapto, C_{1-6} alkyl,
hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, mono or di(C_{1-6} alkyl)amino C_{1-6} alkyl, formyl,
 C_{1-6} alkylcarbonyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl,
20 C_{1-6} alkylthio, cyano, nitro, polyhalo C_{1-6} alkyl, polyhalo C_{1-6} alkyloxy,
aminocarbonyl, $-\text{CH}(=\text{N}-\text{O}-\text{R}^8)$, R^{7a} , $-\text{X}_3-\text{R}^{7a}$ or $\text{R}^{7a}-\text{C}_{1-4}$ alkanediyl-;
 R^{7a} is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic
carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or
aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems
25 may optionally be substituted where possible with one, two, three, four or five
substituents each independently selected from halo, hydroxy, mercapto, C_{1-6} alkyl,
hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, mono or di(C_{1-6} alkyl)amino C_{1-6} alkyl, formyl,
 C_{1-6} alkylcarbonyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl,
20 C_{1-6} alkylthio, cyano, nitro, polyhalo C_{1-6} alkyl, polyhalo C_{1-6} alkyloxy,
aminocarbonyl, or $-\text{CH}(=\text{N}-\text{O}-\text{R}^8)$;
 R^8 is hydrogen, C_{1-4} alkyl optionally substituted with aryl, or aryl;
 R^9 and R^{10} each independently are hydrogen; C_{1-6} alkyl; C_{1-6} alkylcarbonyl;
 C_{1-6} alkyloxycarbonyl; amino; mono- or di(C_{1-6} alkyl)amino; mono- or
35 di(C_{1-6} alkyl)aminocarbonyl; $-\text{CH}(=\text{N}-\text{R}^{11})$ or R^7 , wherein each of the aforementioned
 C_{1-6} alkyl groups may optionally and each individually be substituted with one or two
substituents each independently selected from hydroxy, C_{1-6} alkyloxy,
hydroxy C_{1-6} alkyloxy, carboxyl, C_{1-6} alkyloxycarbonyl, cyano, amino, imino, mono-

or di(C₁-4alkyl)amino, polyhaloC₁-4alkyl, polyhaloC₁-4alkyloxy, polyhaloC₁-4alkylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, R⁷; or

R^9 and R^{10} may be taken together to form a bivalent or trivalent radical of formula

5	-CH ₂ -CH ₂ -CH ₂ -CH ₂ -	(d-1);
	-CH ₂ -CH ₂ -CH ₂ -CH ₂ -CH ₂ -	(d-2);
	-CH ₂ -CH ₂ -O-CH ₂ -CH ₂ -	(d-3);
	-CH ₂ -CH ₂ -S-CH ₂ -CH ₂ -	(d-4);
	-CH ₂ -CH ₂ -NR ¹² -CH ₂ -CH ₂ -	(d-5);
10	-CH ₂ -CH=CH-CH ₂ -	(d-6); or
	=CH-CH=CH-CH=CH-	(d-7);

R^{11} represents cyano; C_{1-4} alkyl optionally substituted with C_{1-4} alkyloxy, cyano, amino, mono- or di(C_{1-4} alkyl)amino or aminocarbonyl; C_{1-4} alkylcarbonyl; C_{1-4} alkyloxycarbonyl; aminocarbonyl; mono- or di(C_{1-4} alkyl)aminocarbonyl;

15 R^{12} represents hydrogen or C_{1-4} alkyl;

R^{13} and R^{14} each independently represent C_{1-6} alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl; C_{2-6} alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl; C_{2-6} alkynyl optionally substituted with cyano, aminocarbonyl or mono- or

20 di(C₁₋₄alkyl)aminocarbonyl:

R^{15} represents C_{1-6} alkyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl;

R^{16} represents C_{1-6} alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl; or R^7 :

25 R¹⁷ represents hydrogen; C₁₋₆alkyl; or C₁₋₆alkyl substituted with aryl;

p is 1 or 2:

aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl

30 C1-6alkylcarbonyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, C1-6alkylthio, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl R⁷ or -X₂-R⁷:

provided that when R^2 represents aminocarbonyl or mono- or

di(C₁₋₄alkyl)aminocarbonyl then R³ represents -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶;

35 cyano; C₁-6alkyl substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁-6alkyl or R⁷; C₁-6alkyl substituted with hydroxy and a second substituent selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰,

-100-

-C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxyC₁₋₆alkyl optionally substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰,

-C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxy substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;

5 C₂₋₆alkenyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;
C₂₋₆alkynyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷;
-C(=N-O-R⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷.

10

10. A compound according to any one of claims 2 to 9 wherein R² represents cyano; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl; C₁₋₆alkyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or
15 C₂₋₆alkynyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl.

11. A compound according to any one of claims 2 to 10 wherein R² represents cyano or aminocarbonyl.

20


12. A compound according to any one of claims 2 to 11 wherein R³ is cyano; aminocarbonyl; C₁₋₆alkyl optionally substituted with cyano or aminocarbonyl; C₁₋₆alkyloxy optionally substituted with cyano or aminocarbonyl; C₂₋₆alkenyl substituted with cyano or aminocarbonyl.


25


13. A compound according to any one of claims 2 to 9 wherein m is 2; R¹ represents hydrogen; R² represents cyano, aminocarbonyl or C₁₋₆alkyl; R³ represents cyano; C₁₋₆alkyl; C₁₋₆alkyl substituted with cyano; C₁₋₆alkyloxy optionally substituted with cyano; C₂₋₆alkenyl substituted with cyano or -C(=O)-NR⁹R¹⁰; each R⁴ independently represents halo, C₁₋₆alkyl or C₁₋₆alkyloxy; X₁ represents -NR⁵- or -O-; R⁵ represents hydrogen; R⁹ and R¹⁰ each independently are hydrogen or C₁₋₆alkyl; or R⁹ and R¹⁰ may be taken together to form a bivalent radical of formula -CH₂-CH₂-O-CH₂-CH₂- (d-3); R¹⁷ is hydrogen; C₁₋₆alkyl optionally substituted with hydroxy, cyano, aminocarbonyl, C₁₋₄alkyloxycarbonyl or aryl; aryl is phenyl substituted with C₁₋₆alkyloxy.

30
35
14. A compound according to claim 2 wherein the compound is selected from

-101-









a *N*-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof.

5 15. A compound according to any one of claims 2 to 14 for use as a medicine.

16 A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 2 to 14.



10 17. A process for preparing a pharmaceutical composition according to claim 16 characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 2 to 14 is intimately mixed with a pharmaceutically acceptable carrier.

15 18. A process for preparing a compound as claimed in claim 2, characterized by
a) reacting an intermediate of formula (II-a) or (II-b) with an intermediate of formula (III) in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent,





-104-

5 with W_1 representing a suitable leaving group, R^{17b} representing C_{1-6} alkyl optionally substituted with aryl, and A and B being defined as in claim 2; b) reacting an intermediate of formula (II'-a) or (II'-b) with an intermediate of formula (III') in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent,




10 with W_1 representing a suitable leaving group, R^{17b} representing C_{1-6} alkyl optionally substituted with aryl, and A and B being defined as in claim 2; c) by converting a compound of formula (I-a) or (I-b) into a compound of formula (I-c) and (I-d) by reaction with a suitable acid,



with R^{17b} representing C_{1-6} alkyl optionally substituted with aryl, and A and B being defined as in claim 2;


-105-

d) converting a compound of formula (I-c) into a compound of formula (I-e) by reaction with an intermediate of formula $R^{17c}-W_2$ in the presence of a suitable base and a suitable solvent,




5 with W_2 representing a suitable leaving group, R^{17c} representing C_{1-6} alkyl optionally substituted with cyano or C_{1-4} alkyloxycarbonyl, and A and B being defined as in claim 2;

e) converting a compound of formula (I-e-1) into a compound of formula (I-f), by reaction with NH_3 in the presence of a suitable solvent,



10 with A and B being defined as in claim 2;


f) converting a compound of formula (I-e-1) into a compound of formula (I-g), by reaction with $NaBH_4$ in the presence of a suitable solvent,



15 with A and B being defined as in claim 2;

g) converting a compound of formula (I-f) into a compound of formula (I-h), by reaction with $POCl_3$ in the presence of a suitable solvent,

-106-



with A and B being defined as in claim 2;

5 or, if desired, further converting compounds of formula (I) into each other
following art-known transformations; or further, if desired, converting the
compounds of formula (I), into a therapeutically active non-toxic acid addition salt
by treatment with an acid, or conversely, converting the acid addition salt form into
the free base by treatment with alkali; or, if desired, preparing stereochemically
isomeric forms, *N*-oxide forms or quaternary amines thereof.

10

19. A product containing (a) a compound as defined in any one of claims 1 to 14, and
(b) another antiretroviral compound, as a combined preparation for simultaneous,
separate or sequential use in the treatment of HIV infection.

15

20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier
and as active ingredients (a) a compound as defined in any one of claims 1 to 14,
and (b) another antiretroviral compound.